Switch Therapeutics


Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’

With an aim to make more precise genetic medicines, Switch Therapeutics emerged from stealth Tuesday with $52 million in venture funding. Switch is built on research into what it describes as “conditionally activated” small interfering RNA. The company claims it can design RNA molecules to be activated only in certain cells, potentially aiding their use in targeting central nervous system diseases.

Read More
Check in later for News updates.